Aktis Oncology

AKTS

Börsenwert 838 Mio. $

Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. AKTS has a cash runway into 2029, supported by $517.3M in cash and a $1.2B+ partnership with Eli Lilly, minimizing near-term dilution risk. AKY-1189 and AKY-2519 offer differentiated radiopharma approaches, with Fast Track status and early human dosimetry data de-risking development.

Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors Enrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027 BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the initiation of the Phase 1b BActinium-2 trial of AKY-25191 in patients with NSCLC and other B7-H3 expressing solid tumor types. The BActinium-2 trial is part of Aktis' clinical development strategy to develop AKY-2519 broadly in several B7-H3 expressing tumors.

Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

A pullback in the AI trade has created opportunities for bargain-hunting investors, according to analysts at Bank of America.

BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the second quarter ended June 30, 2026.

Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4, with lead asset AKY-1189's Phase Ib data expected Q1 2027 as a binary catalyst. My conservative base case yields $12/share equity value, well below the ~$20 market price, implying patient expansion is already priced in.

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will take place on Wednesday, June 3, 2026, at 4:20 p.m. ET.

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data from two separate assessments of AKY-2519 – a clinical imaging and dosimetry assessment in patients with mCRPC and a clinical imaging assessment in patients with various solid tumor types – demonstrated robust tumor uptake and limited normal tissue exposure. These findings, which supported the advancement of a broad clinical development program for AKY-2519, will be presented in two poster presentations at the upcoming 2026 ASCO Annual Meeting, being held May 29 – June 2, 2026, in Chicago.

BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026.

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the BofA Securities Health Care Conference in Las Vegas, Nevada. The presentation will take place on Wednesday, May 13, 2026, at 10:00 a.m. PT.